Teva Pharmaceutical Industries (TEVA) Upgraded by Vetr to Buy

Vetr upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a hold rating to a buy rating in a research note issued to investors on Wednesday. They currently have $22.65 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. BTIG Research boosted their target price on shares of Teva Pharmaceutical Industries to $20.00 in a research report on Friday, December 15th. ValuEngine raised shares of Teva Pharmaceutical Industries from a hold rating to a buy rating in a research report on Monday, October 2nd. Evercore ISI set a $38.00 target price on shares of Teva Pharmaceutical Industries and gave the company a buy rating in a research report on Wednesday, October 25th. Goldman Sachs Group raised shares of Teva Pharmaceutical Industries from a neutral rating to a buy rating and set a $20.00 target price for the company in a research report on Friday, December 15th. Finally, Citigroup raised shares of Teva Pharmaceutical Industries from a neutral rating to a buy rating and set a $24.00 price objective for the company in a research report on Thursday, January 4th. Eight analysts have rated the stock with a sell rating, sixteen have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $21.32.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded down $0.01 during trading on Wednesday, hitting $20.70. 21,430,000 shares of the stock were exchanged, compared to its average volume of 26,730,000. The company has a market capitalization of $20,630.00, a PE ratio of -3.53, a PEG ratio of 1.48 and a beta of 0.54. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $37.94. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, November 2nd. The company reported $0.95 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.03 by ($0.08). Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%. equities analysts anticipate that Teva Pharmaceutical Industries will post 3.72 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. Security National Bank of Sioux City Iowa IA lifted its holdings in shares of Teva Pharmaceutical Industries by 0.4% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after acquiring an additional 87 shares during the last quarter. Bank of Nova Scotia lifted its holdings in shares of Teva Pharmaceutical Industries by 8.3% in the second quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after acquiring an additional 528 shares during the last quarter. Security National Bank of SO Dak lifted its holdings in shares of Teva Pharmaceutical Industries by 3.7% in the second quarter. Security National Bank of SO Dak now owns 17,385 shares of the company’s stock worth $578,000 after acquiring an additional 620 shares during the last quarter. Prudential Financial Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 0.9% in the second quarter. Prudential Financial Inc. now owns 77,973 shares of the company’s stock worth $2,590,000 after acquiring an additional 730 shares during the last quarter. Finally, Caxton Associates LP lifted its holdings in shares of Teva Pharmaceutical Industries by 6.6% in the second quarter. Caxton Associates LP now owns 13,000 shares of the company’s stock worth $432,000 after acquiring an additional 800 shares during the last quarter. 51.96% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries (TEVA) Upgraded by Vetr to Buy” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3147638/teva-pharmaceutical-industries-teva-upgraded-by-vetr-to-buy.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.